Latest Asx Company Filings News

ReNerve Ltd has launched its Empliq product range, marking its entry into the dermal and amniotic tissue repair markets with first sales already recorded and a US launch planned.

ReNerve Limited has launched its Empliq tissue product range in the US, marking a strategic expansion into the growing dermal and amniotic tissue market. The launch complements its existing nerve repair portfolio and sets the stage for further growth.

Kincora Copper Limited has regained 100% ownership of its Mongolian copper-gold assets after Orbminco Limited's withdrawal, positioning itself to advance exploration and development at the promising Bronze Fox project.

Lakes Blue Energy reports strong gas shows at its Wombat-5 well in Victoria’s Gippsland Basin, reinforcing hopes for a commercially viable gas development.

RooLife Group has secured a $64 million two-year supply agreement to distribute its branded coffee and food products in China, reinforcing its expansion strategy in the fast-growing market.

Carnaby Resources has reported a game-changing drill result at its Trek 1 prospect, intersecting 7m at 9.3% copper equivalent, significantly extending known mineralisation beyond the current resource estimate.

Kalamazoo Resources has strategically expanded its Ashburton Gold Project in Western Australia by acquiring the contiguous Xanadu Gold Project and securing a new exploration licence, significantly increasing its exploration footprint amid a strong gold price environment.

Nex Metals Explorations has secured a binding agreement to operate the North Hennai gold project in Egypt’s Eastern Desert, marking its strategic entry into one of the world’s most under-explored mining regions with promising production and exploration potential.

Starpharma has entered a landmark collaboration with Genentech to develop innovative cancer therapies using its proprietary DEP® platform, securing $5.5 million upfront and potential milestones exceeding $560 million.

PYC Therapeutics has restructured its Board and executive team to steer the company through pivotal clinical milestones expected by the end of 2027. The changes signal a strategic push toward late-stage development of its RNA-based drug candidates.

Santana Minerals has reported a significant high-grade gold intercept extending the Rise and Shine deposit 250 metres down plunge, suggesting a potentially much larger orebody and longer mine life.

LTR Pharma has acquired a one-third equity stake in LevOmega Pty Ltd at no cost to shareholders, positioning itself in the growing pharmaceutical-grade omega-3 sector. This strategic move complements LTR’s existing intranasal pharmaceutical portfolio and aligns with its innovation-driven growth strategy.